Table 3.
Univariate analysis of predictive factors associated with positive SBCE findings in overt OGIB patients on antithrombotic agents
| Variables | Reference | OR | 95% CI | p |
|---|---|---|---|---|
| Age (per 1 year increase) | 1.014 | 0.977–1.052 | 0.472 | |
| Male | Female | 1.296 | 0.644–2.607 | 0.468 |
| Hemoglobin level (per 1 g/dl decrease) | 1.164 | 1.000–1.355 | 0.05 | |
| Smoking habit | Non-smoking | 2.197 | 0.726–6.643 | 0.163 |
| Alcohol intake | No intake | 0.888 | 0.360–2.188 | 0.796 |
| NSAID use | Non-user | 1.098 | 0.443–2.723 | 0.84 |
| antiplatelet use | Non-user | 1.53 | 0.646–3.630 | |
| Anticoagulant use | Non-user | 1.007 | 0.499–2.033 | 0.985 |
| PPI use | Non-user | 1.755 | 0.874–3.525 | 0.114 |
| Corticosteroid use | Non-user | 0.399 | 0.070–2.257 | 0.298 |
| Discontinuation of antithrombotics | Continuation | 1.635 | 0.809–3.304 | 0.171 |
| CCI ≥5 | CCI <5 | 3.117 | 0.622–15.618 | 0.167 |
SBCE, small bowel capsule endoscopy; OGIB, obscure gastrointestinal bleeding; OR, odds ratio; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitors; CCI, Charlson comorbidity index.